These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19964736)

  • 41. Fifth toenail clinical response to systemic antifungal therapy is not a marker of successful therapy for other toenails with onychomycosis.
    Avner S; Nir N; Henri T
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1194-6. PubMed ID: 17062030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of terbinafine for toenail onychomycosis.
    Wallace GF
    J Am Podiatr Med Assoc; 2001; 91(10):542. PubMed ID: 11734613
    [No Abstract]   [Full Text] [Related]  

  • 43. Nondermatophytic onychomycosis by Fusarium oxysporum in an immunocompetent host.
    Shah SR; Dalal BD; Modak MS
    J Mycol Med; 2016 Mar; 26(1):e18-21. PubMed ID: 26852190
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
    Gupta AK; Gregurek-Novak T
    Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
    Van Doorslaer EK; Tormans G; Gupta AK; Van Rossem K; Eggleston A; Dubois DJ; De Doncker P; Haneke E
    Dermatology; 1996; 193(3):239-44. PubMed ID: 8944348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Open randomized comparison of itraconazole versus terbinafine in onychomycosis.
    Arenas R; Domínguez-Cherit J; Fernández LM
    Int J Dermatol; 1995 Feb; 34(2):138-43. PubMed ID: 7737776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis.
    Gupta AK; Lynde CW; Konnikov N
    J Am Acad Dermatol; 2001 Mar; 44(3):485-91. PubMed ID: 11209119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significance of non-dermatophyte moulds and yeasts in onychomycosis.
    Ellis DH; Marley JE; Watson AB; Williams TG
    Dermatology; 1997; 194 Suppl 1():40-2. PubMed ID: 9154401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Onychomycosis: treatment perspective.
    Jain S; Sehgal VN
    Int J Dermatol; 2000 Jan; 39(1):10-4. PubMed ID: 10651956
    [No Abstract]   [Full Text] [Related]  

  • 50. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals.
    Baran R; de Doncker P
    Acta Derm Venereol; 1996 Jan; 76(1):82-3. PubMed ID: 8721507
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term evaluation of terbinafine 250 and 500 mg daily in a 16-week oral treatment for toenail onychomycosis.
    De Cuyper C
    Br J Dermatol; 1996 Jul; 135(1):156-7. PubMed ID: 8776393
    [No Abstract]   [Full Text] [Related]  

  • 52. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
    Gupta AK; Fleckman P; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of outcome in the treatment of onychomycosis.
    Sommer S; Sheehan-Dare RA; Goodfield MJ; Evans EG
    Clin Exp Dermatol; 2003 Jul; 28(4):425-8. PubMed ID: 12823307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Continuous terbinafine or pulse itraconazole: a comparative study on onychomycosis.
    Bahadir S; Inalöz HS; Alpay K; Agaoglu C; Cimsit G; Parlat P
    J Eur Acad Dermatol Venereol; 2000 Sep; 14(5):422-3. PubMed ID: 11305391
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical trials of the new antifungal drug therapies.
    Rand S
    J Am Acad Dermatol; 1996 May; 34(5 Pt 1):863. PubMed ID: 8632094
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium.
    Matsumoto T; Tanuma H; Kaneko S; Takasu H; Nishiyama S
    Mycoses; 1995; 38(3-4):135-44. PubMed ID: 7477090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trichophytum rubrum endonyx onychomycosis resistant to standard oral and topical therapies.
    Mulvaney PM; Telang GH; Jellinek N
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine.
    Elewski BE; El Charif M; Cooper KD; Ghannoum M; Birnbaum JE
    J Am Acad Dermatol; 2002 Mar; 46(3):371-5. PubMed ID: 11862171
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis.
    Elewski B; Pollak R; Ashton S; Rich P; Schlessinger J; Tavakkol A
    Br J Dermatol; 2012 Feb; 166(2):389-98. PubMed ID: 21967490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis: a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial.
    Auvinen T; Tiihonen R; Soini M; Wangel M; Sipponen A; Jokinen JJ
    Br J Dermatol; 2015 Oct; 173(4):940-8. PubMed ID: 26036329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.